secwatch / observer
8-K filed May 15, 2026, 5:15 PM ET ticker VTR CIK 0000740260
other material confidence high sentiment neutral materiality 0.60

Ventas ups ATM equity capacity to $3.0B; all 12 directors elected at annual meeting

Ventas, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter J. Bulgarelli

Executive Vice President, Outpatient Medical & Research
VTR · Ventas, Inc.
Effective
2026-05-01
Filed
May 15, 2026, 5:15 PM ET
On May 12, 2026, in connection with his previously disclosed retirement on May 1, 2026, Ventas, Inc. (the “Company”) entered into a separation and release agreement with Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, Ventas, Inc. and President and CEO, Lillibridge Healthcare Services, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter J. Bulgarelli retired as Executive Vice President, Outpatient Medical & Research at Ventas, Inc..

Action
retired
Role
Executive Vice President, Outpatient Medical & Research
Exact text from the filing
On May 12, 2026, in connection with his previously disclosed retirement on May 1, 2026, Ventas, Inc. (the “Company”) entered into a separation and release agreement with Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, Ventas, Inc. and President and CEO, Lillibridge Healthcare Services, Inc.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Ventas, Inc. shareholders approved To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year at the 2026-05-13 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-05-13
Exact text from the filing
Proposal 3: To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Ventas, Inc. shareholders approved To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers at the 2026-05-13 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-05-13
Exact text from the filing
Proposal 2: To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Ventas, Inc. shareholders approved To elect the 12 director nominees named in the Proxy Statement to serve until the 2027 Annual Meeting of Stockholders at the 2026-05-13 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-13
Exact text from the filing
Proposal 1: To elect the 12 director nominees named in the Proxy Statement to serve until the 2027 Annual Meeting of Stockholders
View on SEC.gov

637 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Ventas, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-26-062795
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.